MedTrace Logo

Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP

NCT04576390 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-10-06

No results posted yet for this study

Summary

This study is designed to compare the effects of a single dose Ondansetron 4mg versus Palonosetron 75mcg in the prophylaxis against early \& delayed postoperative nausea and vomiting in the first 48 hours post-operatively in patients undergoing Endoscopic Retrograde Cholangio-Pancreatography (ERCP) to determine the complete response, complete control and failure rates.

Conditions

  • Antiemetic
  • Postoperative Nausea and Vomiting

Interventions

DRUG

Ondansetron 4 mg

Antiemetic drug

DRUG

Palonosetron 75 mcg

Antiemetic drug

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • Theodor Bilharz Research Institute

    lead OTHER

Principal Investigators

  • Omar M. Abou-Hashim, residant · Theodor Bilharz Research Institute

  • Yahia M. Hammad, Lecteurer · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-24
Primary Completion
2021-04-30
Completion
2021-05-25

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04576390 on ClinicalTrials.gov